SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...
CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence interval...
Kynexis, a clinical-stage biotechnology company focused on precision therapeutics for brain diseases, announced that the first patient has been dosed in ...
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-1...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into an ag...
ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...
Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam's lea...
ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...
Tekton Research, a leading multi-site clinical trial company, is proud to announce the addition of three new sites, five new Principal Investigators (PIs...
Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...
Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...
© 2026 Biopharma Boardroom. All Rights Reserved.
